Most people think of Docusign (NASDAQ:DOCU) the way they think about the fax machine: a category-defining product that everyone used, that became invisible, and that nobody thinks about anymore. By 2015 more than 50 million people had used it globally. The pandemic then forced the holdouts in by closing on a house, signing a lease, executing a vendor contract, all of it moved online practically overnight. A 2021 survey by Adobe Digital Insights found that 27% of Americans signed a document electronically for the first time in 2020. That's not growth. That's a last wave.

Docusign owns eSignatures. Market share is high, analyst ratings are solid, and the brand is the category. The problem is that the category is done growing. It's mature, commoditized, and priced like a utility — which is exactly what it's becoming. None of that is what growth investors want to hear.

So Docusign is inventing a new one. The company has been pushing hard on a category it calls Intelligent Agreement Management, or IAM, and it dominated the conversation at their user conference last month. The pitch is ambitious: AI-powered contract lifecycle management that doesn't just capture signatures but actually understands, tracks, and acts on agreements from creation to renewal. Will CISOs and CIOs be impressed?

Here's the thing about the name. IAM has meant Identity and Access Management for the better part of two decades. It's the security category led by Okta and Microsoft Entra ID, one that CIOs treat as non-negotiable infrastructure. Borrowing that acronym is not an accident. Docusign wants agreement management to feel like that: mandatory, not optional.

The execution of that bet shows up in the product stack. Docusign is pairing its Iris AI engine and Agentic Contract Workflows with partnerships like Harvey on the legal AI side and ID.me for identity verification, both announced in May. The message to enterprise buyers: this isn't a signing tool anymore. It's infrastructure.

Getting there requires something that doesn't get mentioned enough: clean data. Autonomous AI agents managing contract lifecycles can't function without reliable pipelines feeding them structured, consistent information. In most large enterprises, those pipelines don't exist. What exists instead is decades of unstructured PDFs sitting in disconnected repositories that nobody has touched since the last system migration.

That cleanup is the real sales obstacle. No CIO is approving an IAM deployment until the data problem is solved first, and those projects are slow, expensive, and politically painful — they touch every department, expose years of sloppy record-keeping, and rarely finish on schedule. Docusign has to sell enterprise legal and procurement teams on the idea that they can run that process at a price that doesn't cause sticker shock before the actual product conversation even begins.

Numbers Look Better Than They Are

The headline numbers are real and worth acknowledging. Quarterly billings crossed $1 billion for the first time. Revenue hit $837 million, up 8% year over year, with non-GAAP EPS of $1.01 beating the $0.95 estimate. Operating margins came in at 30.1% for the full year, free cash flow topped $1 billion, and management rewarded itself by expanding the buyback authorization to $2.6 billion. On paper, a solid quarter. The market shrugged anyway, because cash flow generated from a product category you've already saturated isn't a growth story — and when the best use of $1 billion is buying back your own stock, it signals that nobody inside the company can figure out where else to put it.

Three Red Flags

1. Top Line Growth Ceiling

The guidance is the tell. For fiscal 2027, Docusign set revenue expectations between $3.484 billion and $3.496 billion — a midpoint that works out to 8% year-over-year growth. Eight percent. For a SaaS company still trading on a tech multiple, that number matters more than any single quarter's earnings beat. Single-digit top-line growth at scale isn't a blip; it's a structural signal that the market is treating you differently now. The multiple compression that follows isn't a sentiment problem — it's math.

2. A Saturated Core

Bulls will point to Dollar Net Retention. DNR ticked up to 102% in Q4 from 101% — a sequential improvement that Docusign flagged as a sign of stabilization. Maybe. But 102% means existing enterprise customers are barely spending more than they did last year. The land-and-expand playbook that drove Docusign's pandemic-era growth has stalled. When you're at near-total market saturation for your core product, there's not much left to expand into.

Pricing pressure isn't helping either. Adobe Sign is bundled into Creative Cloud licenses that enterprises already own. Microsoft has been quietly building out eSignature capabilities inside products companies are already paying for. When procurement teams realize they can get 80% of what Docusign does for effectively zero incremental cost, the renewal conversation changes.

3. The Buyback Trick

The $2.6 billion buyback authorization sounds like shareholder-friendly capital allocation. It isn't, not really. In fiscal 2026, Docusign spent $869 million repurchasing its own stock — more than 80% of its free cash flow. That's not a company returning excess capital. That's a company running a treadmill, using buybacks to offset the ongoing dilution created by its own Stock-Based Compensation program. The net share count barely moves. The executives keep their compensation. Shareholders get the bill framed as a gift.

Looking Ahead

The Q1 fiscal 2027 earnings release isn't the event to watch. A beat on cost discipline or a decent international eSignature quarter won't change the underlying problem, and any pop that follows will fade. The only number worth tracking is DNR. If it doesn't move convincingly past 102% across multiple consecutive quarters — with IAM deals actually showing up in the revenue line — nothing else matters. Citi made a similar point earlier this month, flagging that AI-powered workflow automation and embedded document tools from larger platforms are slowly eating into the addressable market Docusign has spent a decade building.

Docusign is profitable. It generates real cash, runs a tight operation, and still owns the category it created. None of that is going away. But the market isn't pricing Docusign on what it has; it's pricing it on what comes next, and right now the answer to that question is a product still in early innings that requires enterprise customers to first solve a data problem they've been ignoring for years.

If you own it, the exit thesis is clearer than the hold thesis right now. If you don't, wait. Not because Q1 will be bad — it probably won't be — but because a decent print changes nothing structural. The stock needs IAM to prove out, and that takes quarters, not weeks.

Disclosure: I have no financial relationship with Docusign or any other companies mentioned in the article

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.